According to the research report, the global allergy diagnostics and therapeutics market size is expected to touch USD 61.60 Billion by 2032, from USD 31.64 Billion in 2022, growing with a significant CAGR of 6.89% from 2023 to 2032.
The allergy diagnostics and therapeutics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global allergy diagnostics and therapeutics in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global allergy diagnostics and therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global allergy diagnostics and therapeutics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2991
This study covers a detailed segmentation of the global allergy diagnostics and therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global allergy diagnostics and therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- R-Biopharm AG
- EUROIMMUN Medizinische Labordiagnostika AG
- DASIT Group SPA
- bioMérieux
- Thermo Fisher Scientific, Inc.
- Stallergenes Greer
- Sun Pharmaceutical Industries Ltd
- Minaris Medical America, Inc.
- Siemens Healthcare GmbH
- AESKU.GROUP GmbH
- Omega Diagnostics Group PLC
- HYCOR Biomedical
- Lincoln Diagnostics, Inc.
- Alcon
- Astellas Pharma Inc.
- HOB Biotech Group Corp., Ltd.
- Danaher
- AbbVie, Inc.
- Allergy Therapeutics
- Sanofi
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
Market Segmentation
By Product
- Instruments
- Consumables
- Services
By Drug Class
- Nasal Anti-cholinergic
- Antihistamines
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Epinephrine
- Immunotherapy
- Decongestants
- Immuno-modulators
By Test
- In vivo Test
- In vitro Test
By Allergen Type
- Food
- Inhaled
- Drug
- Other Allergens
By End-user
- Hospitals
- Diagnostics Labs
- Research & Development Centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global allergy diagnostics and therapeutics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global allergy diagnostics and therapeutics market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Allergy Diagnostics and Therapeutics Market
5.1. COVID-19 Landscape: Allergy Diagnostics and Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Allergy Diagnostics and Therapeutics Market, By Product
8.1. Allergy Diagnostics and Therapeutics Market, by Product, 2023-2032
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Allergy Diagnostics and Therapeutics Market, By Drug Class
9.1. Allergy Diagnostics and Therapeutics Market, by Drug Class, 2023-2032
9.1.1. Nasal Anti-cholinergic
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Antihistamines
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Corticosteroids
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Mast Cell Stabilizers
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Leukotriene Inhibitors
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Epinephrine
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Immunotherapy
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Decongestants
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Immuno-modulators
9.1.9.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Allergy Diagnostics and Therapeutics Market, By Test
10.1. Allergy Diagnostics and Therapeutics Market, by March, 2023-2032
10.1.1. In vivo Test
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. In vitro Test
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Allergy Diagnostics and Therapeutics Market, By By Allergen Type
11.1. Allergy Diagnostics and Therapeutics Market, by By Allergen Type, 2023-2032
11.1.1. Food
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Inhaled
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Drug
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Other Allergens
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Allergy Diagnostics and Therapeutics Market, By End-user
12.1. Allergy Diagnostics and Therapeutics Market, by End-user, 2023-2032
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Diagnostics Labs
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Research & Development Centers
12.1.3.1. Market Revenue and Forecast (2020-2032)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Allergy Diagnostics and Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.3. Market Revenue and Forecast, by Test(2020-2032)
13.1.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.1.5. Market Revenue and Forecast, by End-user (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.1.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.1.6.5. Market Revenue and Forecast, by End-user (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Test(2020-2032)
13.1.7.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.1.7.5. Market Revenue and Forecast, by End-user (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.5. Market Revenue and Forecast, by End-user (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.7. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.8. Market Revenue and Forecast, by End-user (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.10. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.11. Market Revenue and Forecast, by End-user (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.12.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.13. Market Revenue and Forecast, by End-user (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Test(2020-2032)
13.2.14.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.2.15. Market Revenue and Forecast, by End-user (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.5. Market Revenue and Forecast, by End-user (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.7. Market Revenue and Forecast, by End-user (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.9. Market Revenue and Forecast, by End-user (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.10.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.10.5. Market Revenue and Forecast, by End-user (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Test(2020-2032)
13.3.11.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.3.11.5. Market Revenue and Forecast, by End-user (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.5. Market Revenue and Forecast, by End-user (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.7. Market Revenue and Forecast, by End-user (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.9. Market Revenue and Forecast, by End-user (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.10.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.10.5. Market Revenue and Forecast, by End-user (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Test(2020-2032)
13.4.11.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.4.11.5. Market Revenue and Forecast, by End-user (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.3. Market Revenue and Forecast, by Test(2020-2032)
13.5.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.5.5. Market Revenue and Forecast, by End-user (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Test(2020-2032)
13.5.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.5.7. Market Revenue and Forecast, by End-user (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Test(2020-2032)
13.5.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)
13.5.8.5. Market Revenue and Forecast, by End-user (2020-2032)
Chapter 14. Company Profiles
14.1. R-Biopharm AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. EUROIMMUN Medizinische Labordiagnostika AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. DASIT Group SPA
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. bioMérieux
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Stallergenes Greer
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sun Pharmaceutical Industries Ltd
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Minaris Medical America, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Siemens Healthcare GmbH
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AESKU.GROUP GmbH
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments